Literature DB >> 23115295

Inefficient vaginal transmission of tenofovir-resistant HIV-1.

Morgan Chateau1, Michael D Swanson, J Victor Garcia.   

Abstract

Transmission of drug-resistant HIV has been postulated to be a threat to current first-line antiretroviral therapy (ART) regimens and the efficacy of several antiretroviral-based preexposure prophylaxis (PrEP) strategies being tested. Here we evaluated the effect of the common tenofovir (TFV) resistance mutation K65R on vaginal HIV transmission. Our results demonstrate that despite no overt loss of overall replication competence in vivo, this mutation results in significantly reduced mucosal transmission. When transmitted, the mutant virus eventually reverted to the wild type in 2 of 3 animals examined.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115295      PMCID: PMC3554084          DOI: 10.1128/JVI.01777-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  Transmitted HIV-1 drug resistance among young men of color who have sex with men: a multicenter cohort analysis.

Authors:  Lisa B Hightow-Weidman; Christopher B Hurt; Gregory Phillips; Karen Jones; Manya Magnus; Thomas P Giordano; Angulique Outlaw; Daniel Ramos; Elizabeth Enriquez-Bruce; Will Cobbs; Amy Wohl; Melinda Tinsle
Journal:  J Adolesc Health       Date:  2010-08-24       Impact factor: 5.012

3.  Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Authors:  Michael W Melkus; Jacob D Estes; Angela Padgett-Thomas; Joel Gatlin; Paul W Denton; Florence A Othieno; Anja K Wege; Ashley T Haase; J Victor Garcia
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

4.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Authors:  Daniel R Kuritzkes; Christina M Lalama; Heather J Ribaudo; Michelle Marcial; William A Meyer; Cecilia Shikuma; Victoria A Johnson; Susan A Fiscus; Richard T D'Aquila; Bruce R Schackman; Edward P Acosta; Roy M Gulick
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

5.  Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.

Authors:  Jin-fen Li; Jonathan T Lipscomb; Xierong Wei; Neil A Martinson; Lynn Morris; Walid Heneine; Jeffrey A Johnson
Journal:  J Infect Dis       Date:  2011-01-21       Impact factor: 5.226

6.  Implications of HIV PrEP trials results.

Authors:  Fulvia Veronese; Peter Anton; Courtney V Fletcher; Victor DeGruttola; Ian McGowan; Stephen Becker; Sheryl Zwerski; David Burns
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-12       Impact factor: 2.205

7.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

8.  Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.

Authors:  Katyna Borroto-Esoda; Joshua M Waters; Andrew S Bae; Jeanette L Harris; John E Hinkle; Joseph B Quinn; Frank S Rousseau
Journal:  AIDS Res Hum Retroviruses       Date:  2007-08       Impact factor: 2.205

9.  Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice.

Authors:  Christin M Lepus; Thomas F Gibson; Scott A Gerber; Ivana Kawikova; Marian Szczepanik; Jaber Hossain; Vitaly Ablamunits; Nancy Kirkiles-Smith; Kevan C Herold; Ruben O Donis; Alfred L Bothwell; Jordan S Pober; Martha J Harding
Journal:  Hum Immunol       Date:  2009-06-12       Impact factor: 2.850

10.  Transmission networks of drug resistance acquired in primary/early stage HIV infection.

Authors:  Bluma G Brenner; Michel Roger; Daniela D Moisi; Maureen Oliveira; Isabelle Hardy; Reuven Turgel; Hugues Charest; Jean-Pierre Routy; Mark A Wainberg
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

View more
  12 in total

1.  Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.

Authors:  Olivia D Council; Michael D Swanson; Rae Ann Spagnuolo; Angela Wahl; J Victor Garcia
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Authors:  Rikke Olesen; Michael D Swanson; Martina Kovarova; Tomonori Nochi; Morgan Chateau; Jenna B Honeycutt; Julie M Long; Paul W Denton; Michael G Hudgens; Amy Richardson; Martin Tolstrup; Lars Østergaard; Angela Wahl; J Victor Garcia
Journal:  J Clin Invest       Date:  2016-02-08       Impact factor: 14.808

Review 3.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 4.  HIV-specific CD8⁺ T-cell immunity in humanized bone marrow-liver-thymus mice.

Authors:  Timothy E Dudek; Todd M Allen
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 5.  BLT humanized mice as a small animal model of HIV infection.

Authors:  Marshall E Karpel; Christian L Boutwell; Todd M Allen
Journal:  Curr Opin Virol       Date:  2015-06-12       Impact factor: 7.090

6.  A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.

Authors:  Jessica Kenney; Aixa Rodríguez; Larisa Kizima; Samantha Seidor; Radhika Menon; Ninochka Jean-Pierre; Pavel Pugach; Keith Levendosky; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Gabriela Paglini; Thomas M Zydowsky; Melissa Robbiani; José A Fernández Romero
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

7.  In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.

Authors:  Richard L Watkins; Wei Zou; Paul W Denton; John F Krisko; John L Foster; J Victor Garcia
Journal:  Retrovirology       Date:  2013-10-30       Impact factor: 4.602

8.  Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

Authors:  Morgan L Chateau; Paul W Denton; Michael D Swanson; Ian McGowan; J Victor Garcia
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

9.  Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.

Authors:  Charles W Dobard; Sunita Sharma; Mian-Er Cong; Rolieria West; Natalia Makarova; Angela Holder; Chou-Pong Pau; Debra L Hanson; Francis J Novembre; Jose Gerardo Garcia-Lerma; Walid Heneine
Journal:  Retrovirology       Date:  2015-08-08       Impact factor: 4.602

10.  A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV.

Authors:  Larisa Kizima; Aixa Rodríguez; Jessica Kenney; Nina Derby; Olga Mizenina; Radhika Menon; Samantha Seidor; Shimin Zhang; Keith Levendosky; Ninochka Jean-Pierre; Pavel Pugach; Guillermo Villegas; Brian E Ford; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Gabriela Paglini; Natalia Teleshova; Thomas M Zydowsky; Melissa Robbiani; José A Fernández-Romero
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.